文献速递乳腺癌消化系统肿瘤泌尿男性生殖肿瘤

COVID-19大流行与美国癌症筛查缺口的相关性

Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic.
PubMed 文献 · JAMA Oncol · 2021-01-01

东北部降幅最大,西部恢复较慢;最高SES四分位人群筛查下降最明显,导致2020年SES相关筛查差异缩小。远程医疗使用与更高筛查率相关。

要点

  • 2020年4月乳腺癌、结直肠癌、前列腺癌筛查率分别下降90.8%、79.3%、63.4%。
  • 最高SES四分位人群筛查下降最大,2020年SES相关筛查差异缩小。

核心结论

  • COVID-19大流行导致美国乳腺癌、结直肠癌和前列腺癌筛查出现大规模缺口,需公共卫生努力应对。

研究设计与样本

  • 纳入2018年1月至7月、2019年1月至7月及2020年1月至7月数据库中无目标癌症诊断的个体。

主要发现

  • 2020年3-5月三种癌症筛查率较2019年急剧下降,4月降幅最大:乳腺癌-90.8%、结直肠癌-79.3%、前列腺癌-63.4%。
  • 乳腺癌和前列腺癌月度筛查率至7月接近完全恢复。
  • 东北部筛查降幅最大,西部恢复较中西部和南部慢。
  • 最高SES四分位人群筛查下降最大,导致2020年SES相关筛查差异缩小;远程医疗使用与更高筛查率相关。

关键数值与推荐

  • 2020年4月乳腺癌筛查率变化(2020年vs2019年):西部-87.3%(95%CI -87.9%至-86.7%),东北部-94.5%(95%CI -94.9%至-94.1%)。
  • 2020年7月乳腺癌筛查率变化:中西部-0.3%(95%CI -2.1%至1.5%),西部-10.6%(95%CI -12.6%至-8.4%)。
  • 2019年4月前列腺癌筛查率(每10万参保人):最低SES四分位3525(95%CI 3444至3607),最高SES四分位4329(95%CI 4271至4386)。
  • 2020年4月前列腺癌筛查率(每10万参保人):最低SES四分位1535(95%CI 1480至1589),最高SES四分位1338(95%CI 1306至1370)。

临床怎么用

  • 需公共卫生努力解决COVID-19相关的大规模癌症筛查缺口。
  • 可增加不需要操作程序的筛查方式使用。
  • 远程医疗使用与更高癌症筛查率相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The COVID-19 pandemic led to sharp declines in cancer screening. However, the total deficit in screening in the US associated with the pandemic and the differential impact on individuals in different geographic regions and by socioeconomic status (SES) index have yet to be fully characterized. OBJECTIVES: To quantify the screening rates for breast, colorectal, and prostate cancers associated with the COVID-19 pandemic in different geographic regions and for individuals in different SES index quartiles and estimate the overall cancer screening deficit in 2020 across the US population. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study uses the HealthCore Integrated Research Database, which comprises single-payer administrative claims data and enrollment information covering approximately 60 million people in Medicare Advantage and commercial health plans from across geographically diverse regions of the US. Participants were individuals in the database in January through July of 2018, 2019, and 2020 without diagnosis of the cancer of interest prior to the analytic index month. EXPOSURES: Analytic index month and year. MAIN OUTCOMES AND MEASURES: Receipt of breast, colorectal, or prostate cancer screening. RESULTS: Screening for all 3 cancers declined sharply in March through May of 2020 compared with 2019, with the sharpest decline in April (breast, -90.8%; colorectal, -79.3%; prostate, -63.4%) and near complete recovery of monthly screening rates by July for breast and prostate cancers. The absolute deficit across the US population in screening associated with the COVID-19 pandemic was estimated to be 3.9 million (breast), 3.8 million (colorectal), and 1.6 million (prostate). Geographic differences were observed: the Northeast experienced the sharpest declines in screening, while the West had a slower recovery compared with the Midwest and South. For example, percentage change in breast cancer screening rate (2020 vs 2019) for the month of April ranged from -87.3% (95% CI, -87.9% to -86.7%) in the West to -94.5% (95% CI, -94.9% to -94.1%) in the Northeast (decline). For the month of July, it ranged from -0.3% (95% CI, -2.1% to 1.5%) in the Midwest to -10.6% (-12.6% to -8.4%) in the West (recovery). By SES, the largest screening decline was observed in individuals in the highest SES index quartile, leading to a narrowing in the disparity in cancer screening by SES in 2020. For example, prostate cancer screening rates per 100 000 enrollees for individuals in the lowest and highest SES index quartiles, respectively, were 3525 (95% CI, 3444 to 3607) and 4329 (95% CI, 4271 to 4386) in April 2019 compared with 1535 (95% CI, 1480 to 1589) and 1338 (95% CI, 1306 to 1370) in April 2020. Multivariable analysis showed that telehealth use was associated with higher cancer screening. CONCLUSIONS AND RELEVANCE: Public health efforts are needed to address the large cancer screening deficit associated with the COVID-19 pandemic, including increased use of screening modalities that do not require a procedure.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Chen RC, Haynes K, Du S, et al. Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncol. 2021. PMID: 33914015. doi:10.1001/jamaoncol.2021.0884

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。